Induction of immune tolerance to facilitate β cell regeneration in type 1 diabetes

Advanced Drug Delivery Reviews

Volumn 60, Issue 2, 2008, Pages 106-113

  Pasquali, Lorenzo ^a,b   Giannoukakis, Nick ^a   Trucco, Massimo ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Dendritic cells; Diabetes; Gene therapy; Histocompatibility; Regeneration

Indexed keywords

CELLS; INSULIN; NETWORK PROTOCOLS; PATIENT MONITORING;

DENDRITIC CELLS; DIABETIC PATIENTS; GENE THERAPY; IMMUNE TOLERANCE;

MEDICAL PROBLEMS;

C PEPTIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DQ8 ANTIGEN; INSULIN; MAJOR HISTOCOMPATIBILITY ANTIGEN;

AUTOIMMUNITY; CELL MATURATION; CELL REGENERATION; DENDRITIC CELL; GENE THERAPY; HISTOCOMPATIBILITY; HOMEOSTASIS; HORMONE SYNTHESIS; HUMAN; IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIPLE SCLEROSIS; NONHUMAN; PANCREAS ISLET BETA CELL; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ADOPTIVE TRANSFER; ANIMALS; DENDRITIC CELLS; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; INSULIN-SECRETING CELLS;

EID: 37149053510     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2007.08.032     Document Type: Review

References (83)

1. Hirsch I.B. Insulin analogues. N. Engl. J. Med. 352 (2005) 174-183
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329 (1993) 977-986
3. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N. Engl. J. Med. 342 (2000) 381-389
4. Pambianco G., Costacou T., Ellis D., Becker D.J., Klein R., and Orchard T.J. The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 55 (2006) 1463-1469
5. Lipes M.A., Cooper E.M., Skelly R., Rhodes C.J., Boschetti E., Weir G.C., and Davalli A.M. Insulin-secreting non-islet cells are resistant to autoimmune destruction. PNAS 93 (1996) 8595-8600
6. Cheung A.T., Dayanandan B., Lewis J.T., Korbutt G.S., Rajotte R.V., Boylan M.O., Wolfe M.M., and Kieffer T.J. Glucose-dependent insulin release from genetically engineered K cells. Science 290 (2000) 1959-1962
7. Robertson R.P. Islet transplantation as a treatment for diabetes - a work in progress. N. Engl. J. Med. 350 (2004) 694-705
8. Tian C., Bagley J., Cretin N., Seth N., Wucherpfennig K.W., and Iacomini J. Prevention of type 1 diabetes by gene therapy. J. Clin. Invest. 114 (2004) 969-978
9. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., Mathieu C., Kaufman L., Hale G., Gorus F., Goldman M., Walter M., Candon S., Schandene L., Crenier L., De Block C., Seigneurin J.-M., De Pauw P., Pierard D., Weets I., Rebello P., Bird P., Berrie E., Frewin M., Waldmann H., Bach J.-F., Pipeleers D., and Chatenoud L. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 352 (2005) 2598-2608
10. Hess D., Li L., Martin M., Sakano S., Hill D., Strutt B., Thyssen S., Gray D.A., and Bhatia M. Bone marrow-derived stem cells initiate pancreatic regeneration. Nat. Biotechnol. 21 (2003) 763-770
11. Zorina T.D., Subbotin V.M., Bertera S., Alexander A., Haluszczak C., Styche A., Gambrell B., Bottino R., and Trucco M. Recovery of the endogenous beta cell function in the NOD model of autoimmune diabetes. Stem Cells 21 (2003) 377-388
12. Davies J.L., Kawaguchi Y., Bennett S.T., Copeman J.B., Cordell H.J., Pritchard L.E., Reed P.W., Gough S.C.L., Jenkins S.C., Palmer S.M., Balfour K.M., Rowe B.R., Farrall M., Barnett A.H., Bain S.C., and Todd J.A. A genome-wide search for human type 1 diabetes susceptibility genes. Nature 371 (1994) 130-136
13. Egwuagu C.E., Charukamnoetkanok P., and Gery I. Thymic expression of autoantigens correlates with resistance to autoimmune disease. J. Immunol. 159 (1997) 3109-3112
14. Pugliese A., Zeller M., Fernandez Jr. A., Zalcberg L.J., Bartlett R.J., Ricordi C., Pietropaolo M., Eisenbarth G.S., Bennett S.T., and Patel D.D. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat. Genet. 15 (1997) 293-297
15. Vafiadis P., Bennett S.T., Todd J.A., Nadeau J., Grabs R., Goodyer C.G., Wickramasinghe S., Colle E., and Polychronakos C. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat. Genet. 15 (1997) 289-292
16. Bottazzo G.F., Florin-Christensen A., and Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 2 (1974) 1279-1283
17. Giorda R., Peakman M., Tan K.C., Vergani D., and Trucco M. Glutamic acid decarboxylase expression in islet and brain. Lancet 338 (1991) 1469-1470
18. Kaufman D.L., Erlander M.G., Clare-Salzler M., Atkinson M.A., Maclaren N.K., and Tobin A.J. Autoimmunity to two forms of glutamate decarboxylase in insulin-dependent diabetes mellitus. J. Clin. Invest. 89 (1992) 283-292
19. Clarke W.L., Shaver K.A., Bright G.M., Rogol A.D., and W.E. Autoimmunity in congenital rubella syndrome. J. Pediatr. 104 (1984) 370-373
20. Karjalainen J., Martin J.M., Knip M., Ilonen J., Robinson B.H., Savilahti E., Akerblom H.K., and Dosch H.M. A bovine albumin peptide as a possible trigger of insulin-dependent diabetes mellitus. N. Engl. J. Med. 327 (1992) 302-307
21. Conrad B., Weidmann E., Trucco G., Rudert W.A., Ricordi C., Rodriquez-Rilo H., Behboo R., Finegold D., and Trucco M. Evidence for superantigen involvement in insulin-dependent diabetes mellitus etiology. Nature 371 (1994) 351-355
22. Norris J.M., Barriga K., Klingensmith G., Hoffman M., Eisenbarth G.S., Erlich H.A., and Rewers M. Timing of initial cereal exposure in infancy and risk of islet autoimmunity. JAMA 290 (2003) 1713-1720
23. Hyoty H. Environmental causes: viral causes. Endocrinol. Metab. Clin. N. Am. 33 (2004) 27-44
24. Knip M., Veijola R., Virtanen S.M., Hyöty H., Vaarala O., and Åkerblom H.K. Environmental triggers and determinants of type 1 diabetes. Diabetes 54 Suppl 2 (2005) S125-S136
25. Albert L.J., and Inman R.D. Molecular mimicry and autoimmunity. N. Engl. J. Med. 341 (1999) 2068-2074
26. Bach J.F. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr. Rev. 15 (1994) 516-542
27. Shehadeh N.N., LaRosa F., and Lafferty K.J. Altered cytokine activity in adjuvant inhibition of autoimmune diabetes. J. Autoimmun. 6 (1993) 291-300
28. Suarez-Pinzon W., Rajotte R.V., Mosmann T.R., and Rabinovitch A. Both CD4+ and CD8+ T-cells in syngeneic islet grafts in NOD mice produce interferon-gamma during beta-cell destruction. Diabetes 45 (1996) 1350-1357
29. Morel P.A., Vasquez A.C., and Feili-Hariri M. Immunobiology of DC in NOD mice. J. Leukoc. Biol. 66 (1999) 276-280
30. Shortman K., and Naik S.H. Steady-state and inflammatory dendritic-cell development. Nat. Rev. Immunol. 7 (2007) 19-30
31. Fontenot J.D., Gavin M.A., and Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4 (2003) 330-336
32. Bach J.F., and Chatenoud L. Tolerance to islet autoantigens in type 1 diabetes. Annu. Rev. Immunol. 19 (2001) 131-161
33. Todd J.A., Bell J.I., and McDevitt H.O. HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 329 (1987) 599-604
34. Morel P.A., Dorman J.S., Todd J., McDevitt H., and Trucco M. Aspartic acid at position 57 of the HLA-DQ beta chain protects against type I diabetes: a family study. PNAS 85 (1988) 8111-8115
35. Trucco M. To be or not to be Asp 57, that is the question. Diabetes Care 15 (1992) 705-715
36. Kyewski B., and Derbinski J. Self-representation in the thymus: an extended view. Nat. Rev. Immunol. 4 (2004) 688-698
37. McDevitt H. The role of MHC class II molecules in the pathogenesis and prevention of type I diabetes. Adv. Exp. Med. Biol. 490 (2001) 59-66
38. Acha-Orbea H., and McDevitt H.O. The first external domain of the nonobese diabetic mouse class II I-A beta chain is unique. PNAS 84 (1987) 2435-2439
39. Lund T., O'Reilly L., Hutchings P., Kanagawa O., Simpson E., Gravely R., Chandler P., Dyson J., Picard J.K., Edwards A., Kioussis D., and Cooke A. Prevention of insulin-dependent diabetes mellitus in non-obese diabetic mice by transgenes encoding modified I-A beta-chain or normal I-E alpha-chain. Nature 345 (1990) 727-729
40. Hanson M.S., Cetkovic-Cvrlje M., Ramiya V.K., Atkinson M.A., Maclaren N.K., Singh B., Elliott J.F., Serreze D.V., and Leiter E.H. Quantitative thresholds of MHC class II I-E expressed on hemopoietically derived antigen-presenting cells in transgenic NOD/Lt mice determine level of diabetes resistance and indicate mechanism of protection. J. Immunol. 157 (1996) 1279-1287
41. Li H., Kaufman C.L., Boggs S.S., Johnson P.C., Patrene K.D., and Ildstad S.T. Mixed allogeneic chimerism induced by a sublethal approach prevents autoimmune diabetes and reverses insulitis in nonobese diabetic (NOD) mice. J. Immunol. 156 (1996) 380-388
42. Zorina T.D., Subbotin V.M., Bertera S., Alexander A., Styche A.J., and Trucco M. Distinct characteristics and features of allogeneic chimerism in the NOD mouse model of autoimmune diabetes. Cell Transplant 11 (2002) 113-123
43. Trucco M., and Giannoukakis N. Type 1 diabetes: MHC tailored for diabetes cell therapy. Gene. Ther. 12 (2005) 553
44. Zhang C., Todorov I., Lin C.L., Atkinson M., Kandeel F., Forman S., and Zeng D. Elimination of insulitis and augmentation of islet beta cell regeneration via induction of chimerism in overtly diabetic NOD mice. PNAS 104 (2007) 2337-2342
45. Silverstein J., Maclaren N., Riley W., Spillar R., Radjenovic D., and Johnson S. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N. Engl. J. Med. 319 (1988) 599-604
46. Elliott R.B., Crossley J.R., Berryman C.C., and James A.G. Partial preservation of pancreatic beta-cell function in children with diabetes. Lancet 2 (1981) 631-632
47. Bougneres P.F., Landais P., Boisson C., Carel J.C., Frament N., Boitard C., Chaussain J.L., and Bach J.F. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 39 (1990) 1264-1272
48. Belghith M., Bluestone J.A., Barriot S., Megret J., Bach J.F., and Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat. Med. 9 (2003) 1202-1208
49. Herold K.C., Hagopian W., Auger J.A., Poumian-Ruiz E., Taylor L., Donaldson D., Gitelman S.E., Harlan D.M., Xu D., Zivin R.A., and Bluestone J.A. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346 (2002) 1692-1698
50. Herold K.C., Gitelman S.E., Masharani U., Hagopian W., Bisikirska B., Donaldson D., Rother K., Diamond B., Harlan D.M., and Bluestone J.A. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54 (2005) 1763-1769
51. Voltarelli J.C., Couri C.E., Stracieri A.B., Oliveira M.C., Moraes D.A., Pieroni F., Coutinho M., Malmegrim K.C., Foss-Freitas M.C., Simoes B.P., Foss M.C., Squiers E., and Burt R.K. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 297 (2007) 1568-1576
52. Clare-Salzler M.J., Brooks J., Chai A., Van Herle K., and Anderson C. Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer. J. Clin. Invest. 90 (1992) 741-748
53. Feili-Hariri M., Dong X., Alber S.M., Watkins S.C., Salter R.D., and Morel P.A. Immunotherapy of NOD mice with bone marrow-derived dendritic cells. Diabetes 48 (1999) 2300-2308
54. Steptoe R.J., Ritchie J.M., Jones L.K., and Harrison L.C. Autoimmune diabetes is suppressed by transfer of proinsulin-encoding Gr-1+ myeloid progenitor cells that differentiate in vivo into resting dendritic cells. Diabetes 54 (2005) 434-442
55. Adorini L., Penna G., Giarratana N., and Uskokovic M. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases. J. Cell. Biochem. 88 (2003) 227-233
56. Lo J., Peng R.H., Barker T., Xia C.Q., and Clare-Salzler M.J. Peptide-pulsed immature dendritic cells reduce response to beta cell target antigens and protect NOD recipients from type I diabetes. Ann. N. Y. Acad. Sci. 1079 (2006) 153-156
57. Papaccio G., Nicoletti F., Pisanti F.A., Bendtzen K., and Galdieri M. Prevention of spontaneous autoimmune diabetes in NOD mice by transferring in vitro antigen-pulsed syngeneic dendritic cells. Endocrinology 141 (2000) 1500-1505
58. Machen J., Harnaha J., Lakomy R., Styche A., Trucco M., and Giannoukakis N. Antisense oligonucleotides down-regulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells. J. Immunol. 173 (2004) 4331-4341
59. Feili-Hariri M., Falkner D.H., and Morel P.A. Regulatory Th2 response induced following adoptive transfer of dendritic cells in prediabetic NOD mice. Eur. J. Immunol. 32 (2002) 2021-2030
60. Bottino R., Balamurugan A.N., Trucco M., and Starzl T.E. Pancreas and islet cell transplantation. Best. Pract. Res. Clin. Gastroenterol. 16 (2002) 457-474
61. Rother K.I., and Harlan D.M. Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus. J. Clin. Invest. 114 (2004) 877-883
62. Stock P.G., and Bluestone J.A. Beta-cell replacement for type I diabetes. Annu. Rev. Med. 55 (2004) 133-156
63. Shapiro A.M., Lakey J.R., Ryan E.A., Korbutt G.S., Toth E., Warnock G.L., Kneteman N.M., and Rajotte R.V. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 343 (2000) 230-238
64. Ryan E.A., Paty B.W., Senior P.A., Bigam D., Alfadhli E., Kneteman N.M., Lakey J.R., and Shapiro A.M. Five-year follow-up after clinical islet transplantation. Diabetes 54 (2005) 2060-2069
65. Senior P.A., Zeman M., Paty B.W., Ryan E.A., and Shapiro A.M.J. Changes in renal function after clinical islet transplantation: four-year observational study. Am. J. Transplant. 7 (2007) 91-98
66. Giannoukakis N., and Trucco M. Gene therapy for type 1 diabetes: a proposal to move to the next level. Curr. Opin. Mol. Ther. 7 (2005) 467-475
67. Bonner-Weir S., and Weir G.C. New sources of pancreatic beta-cells. Nat. Biotechnol. 23 (2005) 857-861
68. D'Amour K.A., Bang A.G., Eliazer S., Kelly O.G., Agulnick A.D., Smart N.G., Moorman M.A., Kroon E., Carpenter M.K., and Baetge E.E. Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat. Biotechnol. 24 (2006) 1392-1401
69. Sutherland D.E., Sibley R., Xu X.Z., Michael A., Srikanta A.M., Taub F., Najarian J., and Goetz F.C. Twin-to-twin pancreas transplantation: reversal and reenactment of the pathogenesis of type I diabetes. Trans. Assoc. Am. Physicians 97 (1984) 80-87
70. Kodama S., Kuhtreiber W., Fujimura S., Dale E.A., and Faustman D.L. Islet regeneration during the reversal of autoimmune diabetes in NOD mice. Science 302 (2003) 1223-1227
71. Chong A.S., Shen J., Tao J., Yin D., Kuznetsov A., Hara M., and Philipson L.H. Reversal of diabetes in non-obese diabetic mice without spleen cell-derived beta cell regeneration. Science 311 (2006) 1774-1775
72. Nishio J., Gaglia J.L., Turvey S.E., Campbell C., Benoist C., and Mathis D. Islet recovery and reversal of murine type 1 diabetes in the absence of any infused spleen cell contribution. Science 311 (2006) 1775-1778
73. Suri A., Calderon B., Esparza T.J., Frederick K., Bittner P., and Unanue E.R. Immunological reversal of autoimmune diabetes without hematopoietic replacement of beta cells. Science 311 (2006) 1778-1780
74. Gu G., Dubauskaite J., and Melton D.A. Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. Development 129 (2002) 2447-2457
75. Seaberg R.M., Smukler S.R., Kieffer T.J., Enikolopov G., Asghar Z., Wheeler M.B., Korbutt G., and van der Kooy D. Clonal identification of multipotent precursors from adult mouse pancreas that generate neural and pancreatic lineages. Nat. Biotechnol. 22 (2004) 1115-1124
76. Suzuki A., Nakauchi H., and Taniguchi H. Prospective isolation of multipotent pancreatic progenitors using flow-cytometric cell sorting. Diabetes 53 (2004) 2143-2152
77. Bonner-Weir S., Toschi E., Inada A., Reitz P., Fonseca S.Y., Aye T., and Sharmaet A. The pancreatic ductal epithelium serves as a potential pool of progenitor cells. Pediatr. Diabetes 5 Suppl 2 (2004) 16-22
78. Gershengorn M.C., Hardikar A.A., Wei C., Geras-Raaka E., Marcus-Samuels B., and Raaka B.M. Epithelial-to-mesenchymal transition generates proliferative human islet precursor cells. Science 306 (2004) 2261-2264
79. Hao E., Tyrberg B., Itkin-Ansari P., Lakey J., Geron I., Monosov E., Barcova M., Mercola M., and Levine F. Beta-cell differentiation from nonendocrine epithelial cells of the adult human pancreas. Nat. Med. 12 (2006) 310-316
80. Dor Y., Brown J., Martinez O.I., and Melton D.A. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 429 (2004) 41-46
81. Meier J.J., Bhushan A., Butler A.E., Rizza R.A., and Butleret P.C. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration?. Diabetologia 48 (2005) 2221-2228
82. Meier J.J., Lin J.C., Butler A.E., Galasso R., Martinez D.S., and Butler P.C. Direct evidence of attempted beta cell regeneration in an 89-year-old patient with recent-onset type 1 diabetes. Diabetologia 49 (2006) 1838-1844
83. Trucco M. Regeneration of the cell. J. Clin. Invest. 115 (2005) 5-12